Drug intelligence / Profile preview

ethosuximide + Stodal

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This appears to be a combination of ethosuximide, an anticonvulsant medication used to treat absence seizures, and Stodal, which is not mentioned in the provided information. Ethosuximide works by suppressing the paroxysmal three cycle per second spike and wave activity associated with absence seizures, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli. It specifically binds to T-type voltage sensitive calcium channels.

Targets

CaV3 (Caveolin-3)

Beyond the preview

Go deeper on ethosuximide + Stodal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethosuximide + Stodal.

Explore the full profile